Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
ROSELAND, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update highlighting the Company's transformation and growth initiatives under the leadership of its new Chief Executive Officer, Eric Hines. Since joining Milestone Scientific two months ago, Mr. Hines has conducted a comprehensive review of the Company's operations and implemented a series of strategic actions designed to accelerate growth, strengthen its competitive position, and improve operating efficiency. Actions within the dental segment include expanding the Com
ROSELAND, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has received a letter (the "Letter") from NYSE American LLC (the "NYSE American") dated October 8, 2025, stating that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide"). Section 1003(a)(ii) requires a listed company to have stockholders' equity of $4 million or more if it has reported losses from continuing operations and/or net losses in three of
ROSELAND, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Dawood Sayed, M.D., a nationally recognized leader in interventional pain medicine, to its Board of Directors, effective immediately. Dr. Sayed is a Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center and currently serves as Division Chief of Pain Medicine, Director of Interventional Spine Services, and Director of the Center for Neuromodulation. With a robust clinical, academic, and policy background, he brings over a deca
8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2025. Neal Goldman, Chairman of the Board, stated, "We are pleased with our revenue performance in the second quarter, delivering a 25% increase in revenue to $2.3 million, driven by strong international dental sales, which more than doubled year-over-year. We also maintained a strong gross margin of 70%, reflecting the benefits of our high-margin dental business and disciplined cost management.
ROSELAND, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 15th, 2025, to discuss the company's financial results for the second quarter ended June 30, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 470429. A webcast and replay of the call may be accessed
Reports 57% increase in international dental sales for the third quarter of 2024 Advances commercial rollout of CompuFlo® Epidural System across additional pain management clinics following Medicare price assignment in multiple U.S. states ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today reported financial results for the third quarter ended September 30, 2024. Arjan Haverhals, CEO of Milestone Scientific, commented, "We are pleased to report a 22% year-over-year increase in total revenue, reaching $2.5 million for t
ROSELAND, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Dawood Sayed, M.D., a nationally recognized leader in interventional pain medicine, to its Board of Directors, effective immediately. Dr. Sayed is a Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center and currently serves as Division Chief of Pain Medicine, Director of Interventional Spine Services, and Director of the Center for Neuromodulation. With a robust clinical, academic, and policy background, he brings over a deca
ROSELAND. N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Jason Papes as Senior Vice President, Global Head of Sales and Marketing, effective immediately. Mr. Papes brings more than three decades of experience in sales, marketing, and business development within the healthcare industry, including leadership roles at large-cap medical technology companies and successful entrepreneurial ventures. His expertise spans orthopedics, neurology, pain management, and digital imaging, with a track record of building high-perfor
ROSELAND, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Eric C. Hines as Chief Executive Officer, effective immediately. Mr. Hines brings more than 25 years of leadership experience in scaling sales-driven enterprise software companies, serving customers across a range of industries, including healthcare. Most recently, he served as President of North America at Ex Libris, a division of Clarivate, where he led operations across the U.S., Canada, and Latin America and increased annual revenue from approximately $50 m